Trials / Completed
CompletedNCT03230292
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis
A Multicenter, 48-week, Open-label Extension Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to assess the long-term safety, tolerability, and efficacy of bimekizumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bimekizumab | Bimekizumab will be administered subcutaneously in 2 different doses. |
Timeline
- Start date
- 2017-07-03
- Primary completion
- 2019-03-06
- Completion
- 2019-03-06
- First posted
- 2017-07-26
- Last updated
- 2022-07-22
- Results posted
- 2022-03-31
Locations
10 sites across 4 countries: United States, Australia, Canada, Moldova
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03230292. Inclusion in this directory is not an endorsement.